Secondary outcome: Improvement of disease damage ‐ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events associated with treatment · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
Oral methotrexate and oral prednisone showed no clear difference in primary outcome: Adverse effects compared with placebo and oral prednisone (low certainty).
1 finding from 1 review
Secondary outcome: Improvement of disease activity (reduction in lesion size) · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
1 finding from 1 review
Secondary outcome: Improvement of disease damage ‐ not measured · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
1 finding from 1 review
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
Medium‐dose UVA‐1 phototherapy (50 J/cm²) showed no clear difference in primary outcome: Adverse effects compared with low‐dose UVA‐1 phototherapy (20 J/cm²) (low certainty).
1 finding from 1 review
Secondary outcome: Improvement of disease activity (skin softening) · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
Secondary outcome: Improvement of disease damage ‐ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
The review found no eligible studies for this question.
1 finding from 1 review
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
Visual acuity · Participants of any age with either unilateral strabismic, anisometropic, or mixed (strabismic‐refractive) amblyopia; deprivation…
2 findings from 1 review
Adherence · Participants of any age with either unilateral strabismic, anisometropic, or mixed (strabismic‐refractive) amblyopia; deprivation…
1 finding from 1 review
Ocular alignment (different measures and time points reported in the included studies) Assessed at different time points (17 weeks, 24 months, or cessation of treatment) and by the proportions of participants who developed strabismus, showed chang... · Participants of any age with either unilateral strabismic, anisometropic, or mixed (strabismic‐refractive) amblyopia; deprivation…
1 finding from 1 review
Stereo acuity (different measures and time points reported in the included studies) Assessed at different time points (17 weeks, 6 months, 2 years, or at cessation of treatment) and using different measures (TNO stereo test, Titmus fly test, Rando... · Participants of any age with either unilateral strabismic, anisometropic, or mixed (strabismic‐refractive) amblyopia; deprivation…
1 finding from 1 review
Quality of life (different measures and time points reported in the included studies) Assessed at different time points (17 weeks or 6 months) by patient preference or the Amblyopia Treatment Index questionnaire. · Participants of any age with either unilateral strabismic, anisometropic, or mixed (strabismic‐refractive) amblyopia; deprivation…
1 finding from 1 review
Adverse events (reported occurrence of: mild reduction in the visual acuity of the sound eye not requiring treatment; light sensitivity; skin, lid, or conjunctival irritation) Assessed at different time points (17 weeks or 2 years). · Participants of any age with either unilateral strabismic, anisometropic, or mixed (strabismic‐refractive) amblyopia; deprivation…
1 finding from 1 review
Depressive symptoms · various
1 finding from 1 review
Anxiety · various
1 finding from 1 review
General functioning ‐ not measured · various
1 finding from 1 review
Dropout · various
Any early psychological intervention may leads to higher dropouts from treatment compared with active control condition (low certainty).
1 finding from 1 review
Severity of PTSD symptoms · various
1 finding from 1 review